KBC Group NV Increases Stock Position in Evolent Health, Inc. (NYSE:EVH)

KBC Group NV lifted its holdings in shares of Evolent Health, Inc. (NYSE:EVH) by 124.6% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 6,741 shares of the technology company’s stock after acquiring an additional 3,739 shares during the quarter. KBC Group NV’s holdings in Evolent Health were worth $76,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Covestor Ltd lifted its stake in shares of Evolent Health by 138.1% during the 3rd quarter. Covestor Ltd now owns 1,424 shares of the technology company’s stock valued at $40,000 after buying an additional 826 shares in the last quarter. GAMMA Investing LLC lifted its stake in shares of Evolent Health by 5,365.5% during the 3rd quarter. GAMMA Investing LLC now owns 1,585 shares of the technology company’s stock valued at $45,000 after buying an additional 1,556 shares in the last quarter. Dynamic Advisor Solutions LLC purchased a new stake in Evolent Health in the 4th quarter worth approximately $134,000. Point72 Asia Singapore Pte. Ltd. lifted its stake in Evolent Health by 2,471.9% in the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 6,507 shares of the technology company’s stock worth $184,000 after purchasing an additional 6,254 shares in the last quarter. Finally, US Bancorp DE lifted its stake in Evolent Health by 180.3% in the 3rd quarter. US Bancorp DE now owns 6,579 shares of the technology company’s stock worth $186,000 after purchasing an additional 4,232 shares in the last quarter.

Analyst Upgrades and Downgrades

Several research firms have issued reports on EVH. Citigroup lowered their target price on shares of Evolent Health from $21.00 to $18.00 and set a “buy” rating on the stock in a research note on Friday, January 10th. Canaccord Genuity Group lowered their target price on shares of Evolent Health from $23.00 to $16.00 and set a “buy” rating on the stock in a research note on Thursday, January 23rd. Royal Bank of Canada lowered their target price on shares of Evolent Health from $20.00 to $17.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 14th. BTIG Research lowered their target price on shares of Evolent Health from $36.00 to $29.00 and set a “buy” rating on the stock in a research note on Tuesday, December 3rd. Finally, Truist Financial lowered their target price on shares of Evolent Health from $20.00 to $15.00 and set a “buy” rating on the stock in a research note on Wednesday, January 22nd. One equities research analyst has rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $18.38.

Evolent Health Price Performance

EVH stock opened at $9.80 on Monday. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.04 and a current ratio of 1.04. Evolent Health, Inc. has a 52 week low of $9.56 and a 52 week high of $35.00. The firm’s fifty day moving average is $11.04 and its 200 day moving average is $19.69. The firm has a market cap of $1.14 billion, a P/E ratio of -10.76 and a beta of 1.45.

Evolent Health (NYSE:EVH) last announced its quarterly earnings results on Thursday, November 7th. The technology company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.30 by ($0.38). The firm had revenue of $621.40 million during the quarter, compared to the consensus estimate of $625.58 million. Evolent Health had a positive return on equity of 6.30% and a negative net margin of 2.93%. During the same period last year, the business earned $0.19 EPS. Research analysts predict that Evolent Health, Inc. will post 0.22 earnings per share for the current year.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.